Who makes H001 Capsule 200mg-bid?

H001 Capsule 200mg-bid is developed by Livzon Pharmaceutical Group Inc..

What development phase is H001 Capsule 200mg-bid in?

H001 Capsule 200mg-bid is in Phase 2.

Last reviewed 2026-05-14 · How we verify

H001 Capsule 200mg-bid

Livzon Pharmaceutical Group Inc. · Phase 2 active Small molecule

At a glance

Generic name	H001 Capsule 200mg-bid
Sponsor	Livzon Pharmaceutical Group Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

H001 Capsule 200mg-bid CI brief — competitive landscape report
H001 Capsule 200mg-bid updates RSS · CI watch RSS
Livzon Pharmaceutical Group Inc. portfolio CI